The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
|
|
- Julia Howard
- 6 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: fluticasone furoate/vilanterol/umeclidinium bromide Study Number: Title: A Phase III, 24 week, randomized, double-blind, double-dummy, parallel-group study (with an extension to 52 weeks in a subset of subjects) comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI administered once daily in the morning via a dry powder inhaler with budesonide/formoterol 400mcg/12mcg administered twice-daily via a reservoir inhaler in subjects with chronic obstructive pulmonary disease Rationale: Previous clinical studies have assessed the use of triple therapy with an inhaled corticosteroid (ICS), a long acting beta agonist (LABA), and a long acting muscarinic antagonist (LAMA), administered by multiple inhalers, in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). These studies have reported greater improvements in lung function, health-related quality of life, hospitalisation rates, and rescue medication use, compared with dual therapy (ICS/LABA) or LAMA alone, thus supporting the use of triple therapy in COPD. GSK has developed a once-daily triple ICS/LAMA/LABA therapy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg in a single inhaler (ELLIPTA TM ), with the aim of providing a new treatment option for the management of advanced COPD to reduce the exacerbation frequency, allow for a reduced burden of polypharmacy, convenience, and increase the potential for improvement in lung function, health-related quality of life (HRQoL), and symptom control over established dual/monotherapies. Phase: IIIa Study Period: 23 January April 2016 Study Design: This was a randomised, double-blind, double-dummy, parallel-group, multicentre study comparing the efficacy and safety of once-daily FF/UMEC/VI 100/62.5/25 mcg with a twice daily ICS/LABA, budesonide/formoterol (BUD/FOR) 400/12 mcg. The study had three periods: Run-in (2 weeks), Treatment (24 weeks or 52 weeks), and Follow-up (variable duration, could be from 7 days to 52 weeks). All subjects remained on their existing maintenance COPD therapy during the run-in period; eligible subjects were subsequently randomised to one of the two study treatments. All subjects were treated for up to 24 weeks and a subset of approximately 400 subjects was treated for up to 52 weeks. This subset included the first 400 subjects who were randomised and consented to be treated for 52 weeks. Subjects attended clinic visits for screening, randomisation (Day 1), and after 2, 4, 12, and 24 weeks of treatment (and after 36 and 52 weeks of treatment for subjects in the study extension). Subjects who permanently stopped study treatment were not required to withdraw from the study and could continue to have certain safety and efficacy assessments conducted. Centres: A total of 162 centres in 15 countries randomised and treated subjects: 21 centres in Russian Federation, 17 in Ukraine, 17 in Mexico, 16 in Germany, 12 in Greece, 10 in Czech Republic, 10 in Romania, 9 in Bulgaria, 8 in China, 8 in Estonia, 8 in Hungary, 8 in Italy, 6 in Poland, 6 in Republic of Korea, and 6 in Slovakia. Indication: Chronic Obstructive Pulmonary Disease Treatment: Subjects who met the eligibility criteria were randomised (1:1) at Visit 2 (Day 1). The randomisation was stratified based on smoking status. Subjects received one of the following double-blind treatments administered via oral inhalation for 24 weeks (or 52 weeks in a subset of subjects): FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once daily (OD) in the morning and placebo via the Turbuhaler twice daily (BID) OR BUD/FOR 400/12 mcg via the Turbuhaler BID and placebo via the ELLIPTA OD in the morning Objectives: The primary objective was to evaluate the effects of FF/UMEC/VI on lung function and HRQoL compared with BUD/FOR after 24 weeks of treatment. Primary Outcome (Endpoints)/Efficacy: The co-primary endpoints were change from baseline in trough forced expiratory volume in one second (FEV1) at Week 24 and change from baseline in St. George's' Respiratory Questionnaire (SGRQ) Total Score at Week 24. Supporting the co-primary endpoints were the proportion of subjects achieving an increase in trough FEV1 of at least 100 ml from baseline at Week 24 and the proportion of SGRQ responders based on a decrease from baseline of at least 4 units in SGRQ Total Score at Week 24. Secondary Outcome (Endpoints)/Efficacy: Secondary efficacy endpoints included: annual rate of moderate or severe COPD exacerbations (on-treatment), change from baseline in Exacerbations of Chronic Pulmonary Disease Tool- Respiratory Symptoms (EXACT-RS) Score and subscale (breathlessness, cough and sputum, and chest symptoms) scores, Transitional Dyspnoea Index (TDI) Focal Score at Week 24, and percentage of days with a Daily Activity Question score of 2 (did more activities than usual) over Weeks Supporting the secondary analyses were the proportion of EXACT-RS, EXACT-RS Breathlessness, EXACT-RS Cough and Sputum, and EXACT-RS Chest Symptoms responders based on each scale score and the proportion of TDI responders based on TDI focal 1
2 score. Statistical Methods: The Intent-to-Treat (ITT) Population and the Extension (EXT) Population were used for analysis of efficacy and safety data. The ITT Population comprised all randomised subjects, excluding those who were randomised in error who did not receive a dose of study treatment, and included all subjects treated for up to 24 weeks. The EXT Population comprised all subjects in the ITT Population who were enrolled into the subset of subjects (approximately 400) with extension to 52 weeks. Co-primary efficacy endpoints (change from baseline in trough FEV1 and SGRQ Total Score at Week 24) were analysed for the ITT Population using a mixed model repeated measures (MMRM) analysis based on a two-sided hypothesis testing approach. Covariates of treatment group, smoking status (screening), geographical region, visit, baseline value, and baseline-by-visit and treatment group-by-visit interactions were included in the model. To account for multiplicity of the co-primary comparisons, the Hochberg method was used to control overall type I error at α=0.05. Analyses supporting the co-primary endpoints were the proportion of subjects achieving an increase in trough FEV1 of >=100 ml from baseline and the proportion of SGRQ responders based on a pre-defined decrease from baseline >=4 units in SGRQ Total Score. These endpoints were analysed using a generalised linear mixed model with a logit link function using the same covariates as the primary analyses. Secondary endpoint comparisons were not adjusted for multiplicity. The annual rate of moderate/severe COPD exacerbation was analysed using a generalised linear model assuming a negative binomial distribution with time on treatment as an offset variable. Average scores for the EXACT-RS and the three subscales (breathlessness, cough and sputum, and chest symptoms) over 4-week intervals and TDI Focal Score at Week 24 were analysed using a MMRM analysis. The percentage of days with score of 2 on the Daily Activity Question was analysed using an analysis of covariance (ANCOVA) model. The proportions of EXACT-RS responders (decrease from baseline >=2.0), EXACT-RS Breathlessness responders (decrease from baseline >=1.0), EXACT-RS Cough and Sputum responders (decrease from baseline >=0.7), EXACT-RS Chest Symptoms responders (decrease from baseline >=0.7), and TDI responders (score >=1 unit) were analysed using a generalised linear mixed model with a logit link function. Study Population: Male and non-pregnant female subjects at least 40 years of age who were current or former cigarette smokers (at least 10 pack-years at screening) diagnosed with COPD were eligible. Subjects had to demonstrate at screening: A score of >=10 on the COPD Assessment Test (CAT) A post-bronchodilator FEV1 <50% predicted normal OR A post-bronchodilator FEV1 <80% predicted normal and a documented history of >=2 moderate exacerbations or one severe (hospitalised) exacerbation in the previous 12 months A post-salbutamol FEV1/forced vital capacity (FVC) ratio of <0.70. Subjects must also have been receiving daily maintenance treatment for their COPD for at least 3 months prior to screening. Subjects who had a current diagnosis of asthma, COPD caused by α1-antitrypsin deficiency, other significant respiratory disorders (e.g., tuberculosis, lung cancer, pulmonary hypertension, etc), lung resection within 12 months of screening, or other clinically significant diseases in the opinion of the investigator, were not eligible. FF/UMEC/VI 100/62.5/25 BUD/FOR 400/12 Number of Subjects Planned, N Randomised, N ITT Population, N Completed Treatment, n (%) 840 (92) 782 (87) Total Number Subjects Prematurely Discontinued Treatment, n (%) 71 (8) 117 (13) Discontinued due to Adverse Events n (%) 34 (4) 28 (3) Discontinued due to Lack of Efficacy n (%) 10 (1) 37 (4) Discontinued for other reasons n (%) 27 (3) 52 (6) Completed Study, n (%) 866 (95) 842 (94) Total Number Subjects Withdrawn from Study, n (%) 45 (5) 57 (6) Withdrawn due to Adverse Events n (%) 16 (2) 19 (2) Withdrawn due to Lack of Efficacy n (%) 0 0 Withdrawn for other reasons n (%) 29 (3) 38 (4) 2
3 Demographics (ITT Population) FF/UMEC/VI BUD/FOR N Females: Males 233: :663 Mean Age, years (SD) 64.2 (8.56) 63.7 (8.71) White, n (%) 776 (85) 767 (85) Demographics (EXT Population) FF/UMEC/VI BUD/FOR N Females: Males 53:157 58:162 Mean Age, years (SD) 63.7 (7.76) 63.3 (8.43) White, n (%) 210 (100) 219 (>99) Co-Primary Efficacy Results (ITT Population): Trough FEV1 at Week 24 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at Week LS Mean Change from Baseline (SE) (0.0083) (0.0085) Difference (SE) (0.0118) 95% CI 0.148, Adjusted p-value <0.001 SGRQ Total Score at Week 24 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at Week LS Mean change from Baseline (SE) -6.6 (0.45) -4.3 (0.46) Difference (SE) -2.2 (0.64) 95% CI -3.5, -1.0 Adjusted p-value <0.001 Supporting Co-Primary Efficacy Results (Week 24): Proportion of subjects with >=100 ml increase in trough FEV1 FF/UMEC/VI BUD/FOR n Increase, n (%) 453 (50) 184 (21) No increase, n (%) 454 (50) 708 (79) Odds ratio % CI 3.27, 4.97 SGRQ Total Score Responders FF/UMEC/VI BUD/FOR n Responder (>=4 unit decrease in score), n (%) 448 (50) 368 (41) Non-responder, n (%) 456 (50) 525 (59) Odds ratio % CI 1.16, 1.70 Secondary Outcome Results (ITT Population): Annual Rate of Moderate or Severe Exacerbations (up to Week 24) FF/UMEC/VI BUD/FOR n Mean annualised exacerbation rate Ratio % CI 0.49, 0.86 % reduction in annualised rate 35 EXACT-RS Score (Weeks 21-24) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.157) (0.160) 3
4 Difference (SE) (0.224) 95% CI -1.79, EXACT-RS Responders (Weeks 21-24) n Responder (>=2 unit decrease in score), n (%) 413 (47) 317 (37) Non-responder, n (%) 457 (53) 543 (63) Odds ratio % CI 1.30, 1.94 EXACT-RS Breathlessness Score (Weeks 21-24) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.085) (0.087) Difference (SE) (0.122) 95% CI -1.01, EXACT-RS Breathlessness Responders (Weeks 21-24) n Responder (>=1 unit decrease in score), n (%) 410 (47) 294 (34) Non-responder, n (%) 460 (53) 566 (66) Odds ratio % CI 1.42, 2.11 EXACT-RS Cough & Sputum Score (Weeks 21-24) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.046) (0.046) Difference (SE) (0.065) 95% CI -0.35, EXACT-RS Cough & Sputum Responders (Weeks 21-24) n Responder (>=0.7 unit decrease in score), n (%) 406 (47) 325 (38) Non-responder, n (%) 464 (53) 535 (62) Odds ratio % CI 1.23, 1.84 EXACT-RS Chest Symptoms Score (Weeks 21-24) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.050) (0.051) Difference (SE) (0.072) 95% CI -0.50, EXACT-RS Chest Symptoms Responders (Weeks 21-24) n Responder (>=0.7 unit decrease in score), n (%) 346 (40) 267 (31) Non-responder, n (%) 524 (60) 593 (69) Odds ratio % CI 1.27, 1.94 TDI Focal Score at Week 24 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean (SE) 2.29 (0.096) 1.72 (0.099) 4
5 Difference (SE) 0.57 (0.138) 95% CI 0.30, 0.84 TDI Responders (Week 24) n Responder (score of >=1 unit), n (%) 553 (61) 455 (51) Non-responder, n (%) 350 (39) 433 (49) Odds ratio % CI 1.33, 1.95 Daily Activity Question -% days reporting score of 2 (Wks 1-24) FF/UMEC/VI BUD/FOR n LS Mean change from Baseline (SE) 0.0 (0.38) -0.1 (0.39) Difference (SE) 0.1 (0.51) 95% CI -0.9, 1.1 Secondary Outcome Results (EXT Population): Trough FEV1 (L) at Week 52 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at Week LS Mean Change from Baseline (SE) (0.0170) (0.0172) Difference (SE) (0.0242) 95% CI 0.131, Proportion of subjects with >=100 ml increase in trough FEV1 FF/UMEC/VI BUD/FOR n Increase, n (%) 96 (46) 34 (16) No increase, n (%) 114 (54) 185 (84) Odds ratio % CI 3.02, 7.61 SGRQ Total Score at Week 52 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at Week LS Mean change from Baseline (SE) -4.6 (1.01) -1.9 (1.03) Difference (SE) -2.7 (1.44) 95% CI -5.5, 0.2 SGRQ Total Score Responders (Week 52) FF/UMEC/VI BUD/FOR n Responder (>=4 unit decrease in score), n (%) 91 (44) 73 (33) Non-responder, n (%) 118 (56) 146 (67) Odds ratio % CI 1.01, 2.24 Annual Rate of Moderate or Severe Exacerbations (up to Week 52) FF/UMEC/VI BUD/FOR n Mean annualised exacerbation rate Ratio % CI 0.37, 0.85 % reduction in annualised rate 44 EXACT-RS Score (Weeks 49-52) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint
6 LS Mean change from Baseline (SE) (0.370) (0.370) Difference (SE) (0.524) 95% CI -2.45, EXACT-RS Responders (Weeks 49-52) n Responder (>=2 unit decrease in score), n (%) 87 (42) 68 (32) Non-responder, n (%) 118 (58) 145 (68) Odds ratio % CI 1.03, 2.32 EXACT-RS Breathlessness Score (Weeks 49-52) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.207) (0.207) Difference (SE) (0.294) 95% CI -1.45, EXACT-RS Breathlessness Responders (Weeks 49-52) n Responder (>=1 unit decrease in score), n (%) 87 (42) 59 (28) Non-responder, n (%) 118 (58) 154 (72) Odds ratio % CI 1.23, 2.80 EXACT-RS Cough & Sputum Score (Weeks 49-52) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.100) (0.100) Difference (SE) (0.141) 95% CI -0.45, 0.11 EXACT-RS Cough & Sputum Responders (Weeks 49-52) n Responder (>=0.7 unit decrease in score), n (%) 92 (45) 62 (29) Non-responder, n (%) 113 (55) 151 (71) Odds ratio % CI 1.26, 2.94 EXACT-RS Chest Symptoms Score (Weeks 49-52) FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint n with analysable data at timepoint LS Mean change from Baseline (SE) (0.115) (0.115) Difference (SE) (0.163) 95% CI -0.73, EXACT-RS Chest Symptoms Responders (Weeks 49-52) n Responder (>=0.7 unit decrease in score), n (%) 76 (37) 63 (30) Non-responder, n (%) 129 (63) 150 (70) Odds ratio % CI 0.98, 2.33 TDI Focal Score at Week 52 FF/UMEC/VI BUD/FOR n with analysable data at >=1 timepoint
7 n with analysable data at timepoint LS Mean (SE) 1.74 (0.221) 1.39 (0.226) Difference (SE) 0.34 (0.317) 95% CI -0.28, 0.97 TDI Responders (Week 52) n Responder (score of >=1 unit), n (%) 110 (53) 101 (46) Non-responder, n (%) 99 (47) 117 (54) Odds ratio % CI 0.91, 1.99 Daily Activity Question -% days reporting score of 2 (Weeks 1-52) FF/UMEC/VI BUD/FOR n LS Mean change from Baseline (SE) 0.0 (0.70) 0.3 (0.69) Difference (SE) -0.3 (0.95) 95% CI -2.1, 1.6 Safety Results: Adverse Events (AE) information was collected from Day 1 (Randomisation Visit) until the Follow-up Visit/telephone contact was completed or until the Week 24 Visit or Week 52 Visit for subjects who discontinued study treatment but were scheduled to continue in the study until those visits. Additionally, Serious Adverse Events (SAEs) assessed as related to study participation or related to a GSK concomitant medication, were recorded from the time a subject consented to participate in the study up to and including any follow up contact. Number (%) of Subjects Most Frequent Adverse Events On-Therapy FF/UMEC/VI BUD/FOR ITT Population (up to Week 24), N Subjects with any AE(s), n (%) 354 (39) 339 (38) Nasopharyngitis 64 (7) 43 (5) Headache 44 (5) 53 (6) Upper respiratory tract infection 20 (2) 19 (2) COPD 15 (2) 23 (3) Back pain 19 (2) 18 (2) Arthralgia 17 (2) 13 (1) Pneumonia 19 (2) 7 (<1) Pharyngitis 15 (2) 9 (1) Abdominal Pain Upper 9 (<1) 12 (1) Rhinitis 10 (1) 11 (1) Cough 10 (1) 10 (1) Hypertension 8 (<1) 12 (1) Oropharyngeal pain 9 (<1) 10 (1) Influenza 10 (1) 8 (<1) Diarrhoea 9 (<1) 7 (<1) Rhinorrhoea 3 (<1) 12 (1) Blood pressure increased 4 (<1) 8 (<1) EXT Population (up to Week 52), N Subjects with any AE(s), n (%) 100 (48) 122 (55) 7
8 Nasopharyngitis 23 (11) 22 (10) Headache 17 (8) 22 (10) COPD 5 (2) 22 (10) URTI 6 (3) 10 (5) Hypertension 7 (3) 6 (3) Arthralgia 5 (2) 6 (3) Back pain 4 (2) 5 (2) Pneumonia 4 (2) 4 (2) Rhinitis 3 (1) 5 (2) Dizziness 1 (<1) 6 (3) Oropharyngeal pain 6 (3) 1 (<1) Pharyngitis 5 (2) 1 (<1) Respiratory tract infection viral 3 (1) 3 (1) Abdominal pain upper 1 (<1) 3 (1) Blood pressure increased 0 4 (2) Dyspnoea 0 4 (2) Vertigo 0 4 (2) Candida infection 0 3 (1) Gastrooesophageal reflux disease 0 3 (1) Oral fungal infection 0 2 (<1) Serious Adverse Events - On-Therapy Number (%) of Subjects [n subjects with events considered by the investigator to be related to study medication] Subjects with non-fatal SAEs, n (%) [n related] FF/UMEC/VI BUD/FOR ITT Population (up to Week 24), N Any non-fatal SAE, n (%) [n related] 45 (4.9) [2] 47 (5.2) [1] COPD 12 (1.3) 21 (2.3) Pneumonia 8 (0.9) [1] 3 (0.3) Myocardial infarction 0 2 (0.2) Lung neoplasm malignant 0 2 (0.2) Ankle fracture 2 (0.2) 0 Constipation 2 (0.2) 0 Angina pectoris 1 (0.1) 1 (0.1) Transient ischaemic attack 1 (0.1) 1 (0.1) Haemoptysis 0 1 (0.1) Pneumothorax 0 1 (0.1) Pulmonary embolism 0 1 (0.1) Pulmonary oedema 1 (0.1) 0 Appendicitis 1 (0.1) 0 Cellulitis 0 1 (0.1) Infected dermal cyst 1 (0.1) 0 Infective exacerb. of chronic obstruct. airways 0 1 (0.1) disease Lung infection 1 (0.1) [1] 0 Osteomyelitis 1 (0.1) 0 Respiratory tract infection 0 1 (0.1) Tuberculosis 1 (0.1) 0 Urinary tract infection 1 (0.1) 0 Acute coronary syndrome 1 (0.1) 0 Atrial fibrillation 0 1 (0.1) Atrial flutter 0 1 (0.1) [1] Cardiac failure 1 (0.1) [1] 0 Cyanosis 0 1 (0.1) Bladder cancer 1 (0.1) 0 8
9 Brain neoplasm 0 1 (0.1) Brain neoplasm malignant 0 1 (0.1) Lung neoplasm 1 (0.1) 0 Metastases to lung 1 (0.1) 0 Squamous cell carcinoma of lung 0 1 (0.1) Hip fracture 1 (0.1) 0 Humerus fracture 0 1 (0.1) Procedural haemorrhage 1 (0.1) 0 Radius fracture 0 1 (0.1) Gastric ulcer 0 1 (0.1) Intestinal mass 1 (0.1) 0 Epilepsy 0 1 (0.1) Postictal paralysis 0 1 (0.1) Anxiety 1 (0.1) 0 Psychotic disorder 1 (0.1) 0 Haemorrhage urinary tract 1 (0.1) 0 Neprolithiasis 0 1 (0.1) Ureterolithiasis 0 1 (0.1) Coronary artery bypass 1 (0.1) 0 Heart valve replacement 1 (0.1) 0 Inguinal hernia repair 1 (0.1) 0 Deafness 0 1 (0.1) Cataract 0 1 (0.1) Non-cardiac chest pain 0 1 (0.1) Cholecystitis chronic 1 (0.1) 0 Electrocardiogram ST segment elevation 1 (0.1) 0 Intervertebral disc protrusion 1 (0.1) 0 Dermatitis 0 1 (0.1) Peripheral arterial occlusive disease 1 (0.1) 0 EXT Population (up to Week 52), N Any non-fatal SAE, n (%) [n related] 19 (9.0) [0] 27 (12.3) [1] COPD 5 (2.4) 20 (9.1) Pneumonia 4 (1.9) 4 (1.8) [1] Transient ischaemic attack 1 (0.5) 1 (0.5) Lung neoplasm 1 (0.5) 1 (0.5) Pneumothorax 0 1 (0.5) Colon cancer 1 (0.5) 0 Metastases to central nervous system 1 (0.5) 0 Metastases to lung 1 (0.5) 0 Small cell lung cancer 1 (0.5) 0 Acute myocardial infarction 1 (0.5) 0 Atrial fibrillation 1 (0.5) 0 Atrioventricular block complete 1 (0.5) 0 Myocardial ischaemia 0 1 (0.5) Epilepsy 0 1 (0.5) Postictal paralysis 0 1 (0.5) Presyncope 0 1 (0.5) Humerus fracture 0 1 (0.5) Meniscus injury 1 (0.5) 0 Intervertebral disc protrusion 1 (0.5) 0 Osteonecrosis 1 (0.5) 0 Gastric ulcer 1 (0.5) 0 Anxiety 1 (0.5) 0 Inguinal hernia repair 1 (0.5) 0 Subjects with fatal SAEs, n (%) [n related] FF/UMEC/VI BUD/FOR 9
10 ITT Population (up to Week 24), N Any fatal SAE, n (%) [n related] 4 (0.4) [0] 6 (0.7) a [0] Cardiac failure 0 2 (0.2) Acute myocardial infarction 0 1 (0.1) Cardiac failure acute 0 1 (0.1) a Catheter site phlebitis 0 1 (0.1) Sudden cardiac death 1 (0.1) 0 Pneumonia 1 (0.1) 0 Sepsis 0 1 (0.1) Upper gastrointestinal haemorrhage 0 1 (0.1) Metastases to liver 1 (0.1) 0 Haemorrhagic stroke 1 (0.1) 0 Chronic kidney disease 0 1 (0.1) Acute pulmonary oedema 0 1 (0.1) Chronic respiratory failure 0 1 (0.1) EXT Population (up to Week 52), N Any fatal SAE, n (%) [n related] 2 (1.0) [0] 1 (0.5) a [0] Cardiac failure acute 0 1 (0.5) a Sudden cardiac death 1 (0.5) 0 Ischaemic stroke 1 (0.5) 0 a One subject in the EXT Population (BUD/FOR group) died prior to Week 24 and is counted in both the ITT and EXT Populations. Six subjects in each treatment group had fatal SAEs. Conclusion: For the co-primary endpoints, FF/UMEC/VI produced a greater increase in trough FEV1 and a larger decrease in SGRQ Total Score compared with BUD/FOR at Week 24 in the ITT Population; these differences were statistically significant. In support of the co-primary endpoints, larger proportions of subjects treated with FF/UMEC/VI achieved >=100 ml increase in trough FEV1 and responded based on SGRQ Total Score compared with BUD/FOR. Up to Week 24, the annualised rate of moderate or severe exacerbations was reduced by 35% with FF/UMEC/VI compared with BUD/FOR. Greater reductions in COPD symptoms, as measured by EXACT-RS (and subscales) and TDI were observed with FF/UMEC/VI compared with BUD/FOR at the end of the 24-week treatment period and the proportions of responders were greater with FF/UMEC/VI compared with BUD/FOR. There was no difference between treatment groups in the percentage of days reporting a score of 2 on the Daily Activity Question. In the smaller EXT Population, the efficacy results up to Week 52 followed a similar trend to the ITT Population up to Week 24; the annualised rate of moderate or severe exacerbations was reduced by 44%. In the ITT Population (up to week 24), 39% of subjects treated with FF/UMEC/VI and 38% of subjects treated with BUD/FOR experienced at least one AE. In the EXT Population (up to Week 52); 48% of subjects treated with FF/UMEC/VI and 55% of subjects treated with BUD/FOR experienced at least one AE. The most common AEs in both treatment groups in both populations were nasopharyngitis and headache. In the ITT Population, 5% of subjects in each treatment group (45 subjects FF/UMEC/VI and 47 subjects BUD/FOR) experienced non-fatal SAEs. In the EXT Population, 19 subjects (9%) in the FF/UMEC/VI group and 27 subjects (12%) in the BUD/FOR group experienced non-fatal SAEs. The most common non-fatal SAEs in both treatment groups in both populations were COPD and pneumonia. Six subjects (<1%) in each treatment group had fatal SAEs; none were considered related to study treatment by the investigators. 10
Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationEfficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationBlood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS
Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationThe only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis Pharmaceuticals
Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol maleate-glycopyrronium bromide Trial Indication(s) Chronic obstructive pulmonary disease Protocol Number CQVA149A2339 Protocol Title A placebo
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationD DAVID PUBLISHING. 1. Introduction
Journal of Health Science 2 (2014) 591-598 doi: 10.17265/2328-7136/2014.12.004 D DAVID PUBLISHING Comparative Efficacy and Safety of Two Formulations of Ipratropium Bromide (IB) HFA pmdi in Patients with
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSecondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationAclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A15-06 Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aclidiniumbromid/Formoterol
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. COMPOUND NUMBER: PROTOCOL NO.: A397113 PROTOCOL TITLE:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationERS Investor & Analyst Event. Munich Tuesday 9 th September 2014
ERS Investor & Analyst Event Munich Tuesday 9 th September 2014 Darrell Baker SVP, Global Head of Respiratory Agenda GSK s Respiratory Portfolio Eosinophils Research in COPD Eosinophils Clinical Experience
More informationSponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes.
Sponsor Page 1 Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLAF237A2308 Title A multicenter, randomized, double-blind,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNew Medicine Recommendation Trimbow
New Medicine Recommendation Trimbow Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler for treatment of COPD Recommendation: GREEN (restricted) Restriction: Triple therapy
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRelvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma
Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Evidence Summary to support formulary decision making and guideline development Prescribing and
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationANORO ELLIPTA (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease NDA
GlaxoSmithKline Inc. 5 Moore Drive Research Triangle Park, NC 27709 ANORO ELLIPTA (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease NDA 203975 FDA
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSearch for studies: ClinicalTrials.gov Identifier: NCT
ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
2 CLINICAL STUDY SYNOPSIS FINAL REPORT N0. CCD-0402-RS-0002 Title of the study: Evaluation of the 24-hour trough FEV 1 following 7 days of dosing with 2 µg once daily. A multicentre, double-blind, double-dummy,
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOnce-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life
Adv Ther (2018) 35:56 71 https://doi.org/10.1007/s12325-017-0650-4 ORIGINAL RESEARCH Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life Maggie Tabberer. David
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
ORIGINAL ARTICLE COPD A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Tara Rheault 1, Sanjeev Khindri 2, Mitra Vahdati-Bolouri 2, Alison Church 1 and William
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationInternational co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.
Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInternational Co-ordinating investigator None appointed.
Drug product: Budesonide/formoterol SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0673 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0673 Date: 13 June,
More informationAclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationAnoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Anoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Medicines Evidence Pack to Support Formulary and Guidelines Decision Making Prescribing
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More information